On the Record · AbbVie
AbbVie competitors, on the record
The companies whose own annual reports name AbbVie as a competitor, each with the sentence it appears in and the filing it came from.
Who AbbVie names
AbbVie’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.
Who names AbbVie
Companies whose own annual reports name AbbVie as a competitor.
Word for word“In addition, AbbVie, Inc. (Allergan) is a competitor in ocular health.” 20-F for 2025
Word for word“In the treatment of schizophrenia, LYBALVI competes with other oral antipsychotic products, including CAPLYTA (lumateperone) marketed by Johnson & Johnson or its affiliated companies.; REXULTI (brexpiprazole), which is co-marketed by Otsuka Pharm Co. and H. Lundbeck A/S plc; VRAYLAR (cariprazine), which is marketed and sold by Abbvie Inc.; COBENFY (xanomeline and trospium chloride), which is marketed and sold by Bristol-Myers Squibb Company; UZEDY; other oral compounds currently on the market; and generic versions of branded oral products.” 10-K for 2025
Word for word“Our principal competitors in the specialty pharmaceutical market include Supernus Pharmaceuticals, Inc., Jazz Pharmaceuticals PLC, AbbVie Inc., and Alkermes PLC.” 10-K for 2025
Word for word“BRUKINSA AbbVie & Janssen IMBRUVICA U.S., Europe, Asia Pacific & China” 10-K for 2025
Word for word“Our present and potential competitors include major pharmaceutical and biotechnology companies, as well as specialty pharmaceutical firms, including, but not limited to: • Hematology and Oncology: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Gilead, Johnson & Johnson, Merck, Novartis, Roche/Genentech, Sanofi and Takeda; and • Inflammation and Immunology: AbbVie, Amgen, Biogen, Eisai, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer and UCB S.A.” 10-K for 2018
Word for word“With Paragard, we compete with manufacturers of hormonal IUDs including Bayer and AbbVie, Long Acting Reversible Contraceptives including Organon, and other forms of birth control.” 10-K for 2025
Word for word“With respect to Rina-S competitors, Abbvie’s ELAHERE® was the first folate receptor-alpha (FRa) targeting ADC approved, initially in the US and recently in the EU.” 20-F for 2025
Word for word“There remains a minority of oral therapies, under development – most notably deucravacitinib (Sotyktu TM ) (TYK2) from BMS, upadacitinib (Rinvoq TM ) (JAK) from Abbvie and cenerimod (S1P1) from Idorsia/Viatris.” 20-F for 2025
Word for word“Our branded competitors include, among others, AbbVie Inc., Alcon, Bausch + Lomb, Bayer AG, Combe, Compass Diversified, Haleon plc, Kenvue, Mondelez International, Reckitt Benckiser Group plc, Opella, Scholl's Wellness Company, Sunstar Group, The Procter & Gamble Company and Unilever.” 10-K for 2026
Read from AbbVie’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.